Anthropic Appoints Novartis CEO Vas Narasimhan to Board of Directors

Summary

Anthropic's Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of pharmaceutical giant Novartis, to the company's Board of Directors. Narasimhan brings over two decades of experience in medicine and global health, including oversight of the development and approval of more than 35 novel medicines in one of the world's most heavily regulated industries. With this appointment, Trust-appointed directors now constitute a majority of Anthropic's Board, reinforcing the company's governance structure as a Public Benefit Corporation committed to balancing shareholder interests with its mission to develop AI for humanity's long-term benefit. Narasimhan's expertise in responsibly scaling breakthrough technology aligns with Anthropic's focus on deploying AI safely and at scale, particularly in healthcare and life sciences applications.

• The Long-Term Benefit Trust functions as an independent governance body with no financial stake in Anthropic, ensuring the company balances stakeholder and public benefit interests

Editorial Opinion

Appointing a seasoned pharmaceutical executive to oversee AI governance represents a thoughtful move by Anthropic to institutionalize responsible deployment practices. Narasimhan's track record in navigating complex regulatory environments and bringing life-saving medicines to scale offers valuable perspective on responsible innovation—a critical lesson as AI systems become increasingly powerful. This appointment signals that Anthropic is serious about embedding real-world accountability into its governance structure, not merely paying lip service to responsible AI principles.